SCHEMBL5318082

SCHEMBL5318082

CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.74
MAPT P10636 2/20 0.74
MEN1 O00255 6/20 0.74
KMT2A Q03164 6/20 0.74
ALDH1A1 P00352 6/20 0.74
LMNA P02545 3/20 0.74
ALOX12 P18054 1/20 0.74
CA12 O43570 1/20 0.71
CA9 Q16790 1/20 0.71
GAA P10253 2/20 0.68
MAPK1 P28482 1/20 0.68
GFER P55789 1/20 0.68
KDM4E B2RXH2 2/20 0.67
KDM1A O60341 1/20 0.67
CYP3A4 P08684 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
PKM P14618 1/20 0.64
SMN1; SMN2 Q16637 2/20 0.63
CA1 P00915 1/20 0.63
CA2 P00918 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8240386 0.88 MAPT (0.70) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL3402411 0.85 MEN1 (0.91) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL5317234 0.85 MAPT (0.77) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL3767094 0.85 MAPT (1.00) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL9365750 0.85 PKM (0.73) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL12338982 0.85 MAPT (1.00) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL4085457 0.85 MAPT (0.77) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL5315171 0.84 MAPT (0.74) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL2152851 0.84 MAPT (0.74) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL28262517 0.84 MAPT (0.74) HPGDMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007067994-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2007-06-14 WO disclosed
WO-2007067993-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2007-06-14 WO disclosed
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC (US) 2007-06-14 US disclosed
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC (US) 2007-06-14 US disclosed
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC (US) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135431-A1 INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE HDAC6, HDAC1, HDAC3 HPGD 806/4885MAPT 401/4885MEN1 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.